SCHEMBL12293612

SCHEMBL12293612

O=C(O)c1sccc1S(=O)(=O)Nc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.76
CYP3A4 P08684 2/20 0.76
KMT2A Q03164 2/20 0.76
TSHR P16473 1/20 0.76
NPSR1 Q6W5P4 1/20 0.59
HSD17B10 Q99714 1/20 0.57
KDM4E B2RXH2 1/20 0.57
EDNRA P25101 6/20 0.54
LMNA P02545 1/20 0.53
FABP4 P15090 2/20 0.51
FABP3 P05413 1/20 0.51
FABP2 P12104 1/20 0.51
FABP5 Q01469 1/20 0.51
PPARG P37231 1/20 0.49
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49
PTK2B Q14289 1/20 0.49
EDNRB P24530 1/20 0.48
MAPT P10636 1/20 0.47
IL1RN P18510 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12293620 0.88 MEN1 (0.59) MEN1CYP3A4KMT2ATSHRNPSR1
SCHEMBL3917516 0.86 MEN1 (1.00) MEN1CYP3A4KMT2ATSHRNPSR1
SCHEMBL12293618 0.85 MEN1 (0.57) MEN1CYP3A4KMT2ATSHRNPSR1
SCHEMBL533130 0.85 PPARG (0.66) MEN1CYP3A4KMT2ATSHREDNRA
SCHEMBL12293616 0.85 MEN1 (0.57) MEN1CYP3A4KMT2ATSHRHSD17B10
SCHEMBL12293607 0.84 MEN1 (0.56) MEN1CYP3A4KMT2ATSHRNPSR1
SCHEMBL1936832 0.82 MEN1 (0.57) MEN1CYP3A4KMT2ATSHRHSD17B10
SCHEMBL27030597 0.80 EDNRA (0.66) MEN1CYP3A4KMT2ATSHRKDM4E
SCHEMBL14243557 0.79 PPARG (0.73) MEN1CYP3A4KMT2ATSHRNPSR1
SCHEMBL11532397 0.78 LMNA (0.62) MEN1CYP3A4KMT2ATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895608-B2 Sulfonamide anti-viral compounds Kineta, Inc. (US) 2014-11-25 US disclosed
US-8895608-B2 Sulfonamide anti-viral compounds Kineta, Inc. (US) 2014-11-25 US disclosed
US-20130039945-A1 Anti-Viral Compounds Kineta, Inc. (US) 2013-02-14 US disclosed
US-20130039945-A1 Anti-Viral Compounds Kineta, Inc. (US) 2013-02-14 US disclosed
WO-2011133729-A2 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130039945-A1 Anti-Viral Compounds MAVS, EIF2AK2, IRF3 MEN1 4873/4885CYP3A4 4242/4885KMT2A 3571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.